Fig. 4: PSMD14 stabilizes BCKDK by deubiquitination. | Cell Death & Differentiation

Fig. 4: PSMD14 stabilizes BCKDK by deubiquitination.

From: Targeting the PSMD14-BCKDK pathway overcomes immune suppression and enhances CAR-NK infiltration in glioblastoma

Fig. 4: PSMD14 stabilizes BCKDK by deubiquitination.

A HEK293T cells co-expressing Flag-BCKDK, HA-ubiquitin, and Myc-PSMD14 were treated with MG132 (10 μM, 6 h); BCKDK polyubiquitination assessed by Flag-IP. B, C U251 cells treated with OPA (10 μM, 24 h) or stably expressing PSMD14 shRNA were exposed to MG132 and subjected to BCKDK-IP to assess ubiquitination. D HEK293T cells co-expressing Flag-BCKDK, Myc-PSMD14, and wild-type or mutant HA-ubiquitin were analyzed for BCKDK ubiquitination after MG132 treatment. E PSMD14 catalytic mutants (H113Q, H115Q, C120S) reduce deubiquitination of BCKDK in HEK293T cells. F Ubiquitination of BCKDK K48R and K184R mutants assessed in HEK293FT cells co-expressing PSMD14 and HA-ubiquitin. G TRIM21 wild-type and LD mutant co-expression in HEK293T cells analyzed for effect on BCKDK ubiquitination. H TRIM21 knockdown in U251 cells decreases BCKDK ubiquitination following MG132 treatment.

Back to article page